September 1, 2025 Teva Pharmaceuticals achieved a landmark milestone when the US Food and Drug Administration (FDA) approved a first-of-its-kind launch of a generic glucagon-like peptide-1 (GLP-1)
Semaglutide for managing overweight and obesity (TA875) Chapter 1: Recommendations
The before-and-after photos shown above represent actual patients treated through physician-supervised medical weight loss programs
When the validation training exceeded the specified threshold of 0.99, the training procedure was terminated
The packaging advertises a GLP-1 7-in-1 formula with sweeping health claims: appetite suppression, sugar regulation, cardiovascular benefits, intestinal health and anti-aging effects
Every Found clinician is board-certified and trained in metabolic medicine because lasting weight care requires real expertise, not just a prescription